Meridian Bioscience Comments on Recent FDA Matters Related to Magellan Diagnostics
CINCINNATI, June 30, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following clarifying comments regarding a June 29, 2017 letter from a group of U.S. Senators to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). The letter requested information on an […]